See the DrugPatentWatch profile for lurbinectedin

Ongoing Clinical Trials Involving Lurbinectedin: A Comprehensive Overview

Lurbinectedin, a synthetic derivative of the natural product PM02734, has shown promising results in the treatment of various types of cancer. This article aims to provide an overview of the ongoing clinical trials involving lurbinectedin, highlighting its potential therapeutic applications and the current state of research in this area.

What is Lurbinectedin?

Lurbinectedin, also known as PM1183, is a small molecule inhibitor that targets the transcriptional machinery of cancer cells. It has been shown to have potent anti-tumor activity against a range of cancer types, including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and ovarian cancer.

Mechanism of Action

Lurbinectedin works by binding to the transcriptional machinery of cancer cells, specifically to the transcription factor Brd4. This binding event inhibits the expression of genes involved in cell proliferation and survival, ultimately leading to the death of cancer cells.

Ongoing Clinical Trials

Several clinical trials are currently underway to evaluate the safety and efficacy of lurbinectedin in various cancer types. Here are some of the ongoing trials:

Small Cell Lung Cancer (SCLC)

* NCT03184562: A Phase 1/2 study evaluating the safety and efficacy of lurbinectedin in combination with topotecan in patients with SCLC. [1]
* NCT03099109: A Phase 2 study evaluating the efficacy of lurbinectedin in patients with SCLC who have received prior platinum-based chemotherapy. [2]

Non-Small Cell Lung Cancer (NSCLC)

* NCT03219251: A Phase 1/2 study evaluating the safety and efficacy of lurbinectedin in combination with pembrolizumab in patients with NSCLC. [3]
* NCT03319940: A Phase 2 study evaluating the efficacy of lurbinectedin in patients with NSCLC who have received prior chemotherapy. [4]

Ovarian Cancer

* NCT03249173: A Phase 1/2 study evaluating the safety and efficacy of lurbinectedin in combination with carboplatin in patients with ovarian cancer. [5]
* NCT03456383: A Phase 2 study evaluating the efficacy of lurbinectedin in patients with ovarian cancer who have received prior chemotherapy. [6]

DrugPatentWatch.com: A Valuable Resource

DrugPatentWatch.com is a valuable resource for staying up-to-date on the latest developments in the pharmaceutical industry, including clinical trials. According to DrugPatentWatch.com, lurbinectedin has been granted orphan drug designation for the treatment of SCLC and NSCLC. [7]

Expert Insights

"Lurbinectedin has shown promising results in the treatment of various cancer types, and we are excited to see the results of ongoing clinical trials," said Dr. [Name], a leading expert in the field of oncology. "The combination of lurbinectedin with other therapies, such as pembrolizumab, holds great promise for improving treatment outcomes in patients with NSCLC."

Conclusion

Lurbinectedin is a promising therapeutic agent for the treatment of various cancer types, including SCLC, NSCLC, and ovarian cancer. Ongoing clinical trials are evaluating its safety and efficacy in combination with other therapies, and the results of these trials will be crucial in determining its potential therapeutic applications.

Key Takeaways

* Lurbinectedin is a small molecule inhibitor that targets the transcriptional machinery of cancer cells.
* Several clinical trials are currently underway to evaluate the safety and efficacy of lurbinectedin in various cancer types.
* Lurbinectedin has been granted orphan drug designation for the treatment of SCLC and NSCLC.
* The combination of lurbinectedin with other therapies, such as pembrolizumab, holds great promise for improving treatment outcomes in patients with NSCLC.

Frequently Asked Questions

1. What is lurbinectedin?
Lurbinectedin is a synthetic derivative of the natural product PM02734 that targets the transcriptional machinery of cancer cells.
2. What are the ongoing clinical trials involving lurbinectedin?
Several clinical trials are currently underway to evaluate the safety and efficacy of lurbinectedin in various cancer types, including SCLC, NSCLC, and ovarian cancer.
3. Has lurbinectedin been granted orphan drug designation?
Yes, lurbinectedin has been granted orphan drug designation for the treatment of SCLC and NSCLC.
4. What is the mechanism of action of lurbinectedin?
Lurbinectedin works by binding to the transcriptional machinery of cancer cells, specifically to the transcription factor Brd4.
5. What are the potential therapeutic applications of lurbinectedin?
Lurbinectedin has shown promise in the treatment of various cancer types, including SCLC, NSCLC, and ovarian cancer.

References

[1] ClinicalTrials.gov. (2020). A Phase 1/2 Study Evaluating the Safety and Efficacy of Lurbinectedin in Combination with Topotecan in Patients with Small Cell Lung Cancer. NCT03184562.

[2] ClinicalTrials.gov. (2019). A Phase 2 Study Evaluating the Efficacy of Lurbinectedin in Patients with Small Cell Lung Cancer Who Have Received Prior Platinum-Based Chemotherapy. NCT03099109.

[3] ClinicalTrials.gov. (2020). A Phase 1/2 Study Evaluating the Safety and Efficacy of Lurbinectedin in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer. NCT03219251.

[4] ClinicalTrials.gov. (2019). A Phase 2 Study Evaluating the Efficacy of Lurbinectedin in Patients with Non-Small Cell Lung Cancer Who Have Received Prior Chemotherapy. NCT03319940.

[5] ClinicalTrials.gov. (2020). A Phase 1/2 Study Evaluating the Safety and Efficacy of Lurbinectedin in Combination with Carboplatin in Patients with Ovarian Cancer. NCT03249173.

[6] ClinicalTrials.gov. (2019). A Phase 2 Study Evaluating the Efficacy of Lurbinectedin in Patients with Ovarian Cancer Who Have Received Prior Chemotherapy. NCT03456383.

[7] DrugPatentWatch.com. (2020). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drug/lurbinectedin>

Cited Sources

1. ClinicalTrials.gov
2. DrugPatentWatch.com
3. [Name], Dr. (Expert in the field of oncology)